statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting Aadi Bioscience to Present New...

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,130,000...

Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI  Free Report)  Equities research analysts at HC Wainwright issued their Q1 2024 EPS estimates for Aadi Bioscience in a note issued to investors on...

Aadi Bioscience, Inc. Forecasted to Post Q1 2024 Earnings of ($0.62) Per Share (NASDAQ:AADI)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aadi Bioscience presents new subgroup analysis in advanced malignant PEComa

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) Aadi Bioscience...

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Aadi Bioscience ( NASDAQ:AADI ) Full Year 2023 Results Key Financial Results Revenue: US$24.4m (up 60% from FY 2022...

Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Q4 2023 Aadi Bioscience Inc Earnings Call Transcript

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year...

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

Aadi Bioscience (NASDAQ:AADI) est cens e annoncer ses derniers b n fices ce mercredi. Voici le guide essentiel de Benzinga\ au rapport de r sultats du quatri me trimestre de Aadi Bioscience.
R sultat...

Panorama des b n fices de Aadi Bioscience

Aadi Bioscience, Inc. ( NASDAQ:AADI ) shareholders are no doubt pleased to see that the share price has bounced 28% in...

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Volume	5,276.00
52-Wk High	$8.60
52-Wk Low	$1.55

AADI Aadi Bioscience Inc

About

Feed

News

Earnings

Fundamentals